Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PORT-77 · 2 trials · 2 indications
Change over the course of the study in plasma PPIX concentrations
| Arm | Type | Description |
|---|---|---|
| PORT-77 | EXPERIMENTAL | Active |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| PORT-77 | DRUG | Active oral dose form |
| Placebo | DRUG | Matching inactive oral dose form |
Major Inclusion Criteria: 1. BMI ≥18.0 and ≤40.0 kg/m2 and weight ≥50 kg on Day -1. 2. Nonsmoker or willing to refrain from the use of nicotine or tobacco-containing products for at least 30 days prior to the first dose of study drug based on participant self-reporting and agrees to refrain from th...
PORT-77 is an investigational small molecule being developed for erythropoietic protoporphyria (EPP), a rare disease. It has been studied in healthy adult participants and in adults with EPP. PORT-77 is not approved and remains in clinical development.
PORT-77 is being developed by BridgeBio Pharma, Inc., a biopharmaceutical company traded on NASDAQ under the ticker BBIO. The company is conducting clinical trials of PORT-77 in the United States.
PORT-77 is in Phase 2 clinical development for erythropoietic protoporphyria (EPP). It has completed a Phase 1 study in healthy participants and a Phase 2a study in adults with EPP. PORT-77 is investigational and not yet approved.
PORT-77 has been studied in two completed trials: NCT06346509, a Phase 1 single and multiple ascending dose study in healthy adults, and NCT06971900, the GATEWAY Phase 2a study in adults with erythropoietic protoporphyria. Both trials were conducted in the United States.
No alternative names for PORT-77 have been disclosed. It is identified by the code name PORT-77 in clinical trial registrations and is being developed by BridgeBio Pharma.